Recently, newer options have been more successful in individuals with a BMI 30 kg/m 2 or 27 kg/m 2 with obesity-related comorbidities such as type 2 diabetes, high blood pressure, high cholesterol or obstructive sleep apnea
Jeff Giullian, chief medical officer for DaVita, said at the time, adding, Based on the inclusion criteria for study participants, we believe there may be limited application of the FLOW study findings to the overall CKD patient population. He argued that the inclusion requirements necessary to partake in the FLOW trial, such as needing to be on a standard kidney disease treatment and have a certain amount of protein in the urine, were attributable to a narrow subset less than 10% of all current CKD patients
a journal of cerebral circulation
Supplementation with citrulline is a potent adjunct to glutathione
Five WT mice and six GLP-1R KO mice were imaged with DMRS
Cutting back or eliminating alcohol can help protect your pancreas